Literature DB >> 3886698

Enzyme immunoassay of serum beta-2-microglobulin levels in various histological forms of leprosy with special reference to its elevation in type I and type II lepra reactions.

K Saha, A Bhatnagar, V K Sharma, A K Chakrabarty.   

Abstract

The mean beta-2-microglobulin level in serum (3,362 +/- 2,494 micrograms/liter) for 76 leprosy patients, including 9 borderline-tuberculoid, 8 borderline-borderline, 9 borderline-lepromatous, and 16 lepromatous-lepromatous patients and 34 patients with type I or type II lepra reactions, was significantly higher (P less than 0.001) than that (2,122 +/- 1,844 micrograms/liter) for 35 normal subjects. It decreased significantly (P less than 0.001) as the disease glided down from borderline tuberculoid (3,173 +/- 899 micrograms/liter) to the lepromatous end (1,813 +/- 1,391 micrograms/liter). At the onset of type I or type II reaction, the mean beta-2-microglobulin level in serum increased (4,447 +/- 2,863 micrograms/liter), and it remained unchanged (4,433 +/- 2,623 micrograms/liter) after clinical remission. The beta-2-microglobulin level in serum decreased in 55.5% of the patients tested after subsidence of reaction. The level was significantly higher in patients with type II reactions (5,433 +/- 3,299 micrograms/liter) than in patients with type I reactions (3,558 +/- 2,171 micrograms/liter).

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3886698      PMCID: PMC271746          DOI: 10.1128/jcm.21.4.658-661.1985

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  22 in total

1.  Serum 2 -microglobulin in various disorders.

Authors:  P E Evrin; L Wibell
Journal:  Clin Chim Acta       Date:  1973-01-24       Impact factor: 3.786

2.  Changes in renal function during reactive phases of lepromatous leprosy.

Authors:  G Thomas; A B Karat; P S Rao; C Prathapkumar
Journal:  Int J Lepr Other Mycobact Dis       Date:  1970 Apr-Jun

3.  Beta 2-microglobulin monitoring after renal transplantation.

Authors:  R T Schweizer; R Moore; S A Bartus; L Bow; J Hayden
Journal:  Transplant Proc       Date:  1981-09       Impact factor: 1.066

4.  An appraisal of third complement component (C3) and breakdown product (C3d) in erythema nodosum leprosum (ENL).

Authors:  K Saha; A K Chakraborty; V Sharma; V N Sehgal
Journal:  Lepr Rev       Date:  1982-12       Impact factor: 0.537

5.  Sequential renal functions in leprosy.

Authors:  A K Bajaj; S C Gupta; S N Sinha; D C Govil; U C Gaur
Journal:  Lepr India       Date:  1981-04

6.  A study of percutaneous renal biopsy in lepromatous leprosy.

Authors:  S C Gupta; A K Bajaj; D C Govil; S N Sinha; R Kumar
Journal:  Lepr India       Date:  1981-04

7.  Immunologic aspects of leprosy as related to leucocytic isoantibodies and platelet aggregating factors.

Authors:  K Saha; R N Dutta; M M Mittal
Journal:  Int J Lepr Other Mycobact Dis       Date:  1975 Jul-Sep

8.  Classification of leprosy according to immunity. A five-group system.

Authors:  D S Ridley; W H Jopling
Journal:  Int J Lepr Other Mycobact Dis       Date:  1966 Jul-Sep

9.  Identification of components of IC purified from human sera. I. Immune complexes purified from sera of patients with SLE.

Authors:  M A Maire; M Barnet; N Carpentier; P A Miescher; P H Lambert
Journal:  Clin Exp Immunol       Date:  1983-02       Impact factor: 4.330

10.  Aberrant immunoregulatory control of B lymphocyte function in lepromatous leprosy.

Authors:  W E Bullock; S Watson; K E Nelson; V Schauf; S Makonkawkeyoon; R R Jacobson
Journal:  Clin Exp Immunol       Date:  1982-07       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.